PRAGUE--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive tests to monitor immune status in transplant recipients and autoimmune diseases, today announced positive clinical results from the Company’s European-based Cardiac Allograft Rejection Gene Expression Observational (CARGO) II Study of AlloMap® Molecular Expression Testing. AlloMap is XDx’s FDA-cleared and CE-marked, easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient’s risk of acute cellular rejection without requiring the use of endomyocardial biopsy. Results from the study confirmed the AlloMap test performance characteristics previously established in the first U.S.-based CARGO study.
